Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Curr Oncol Rep. 2020 Sep 23;22(12):120. doi: 10.1007/s11912-020-00978-9.
Isocitrate dehydrogenase (IDH) mutation status has important prognostic implications in glioma patients, with IDH wild-type (IDH-WT) gliomas being associated with worse prognosis and shorter survival when compared with IDH mutant (IDH-mut) gliomas. Optimization of quality of life is a priority in the management of glioma patients. The goal of this systematic review was to identify studies that explored the association of IDH mutation status with patient-reported outcomes (PROs) and cognitive functioning of glioma patients.
Studies that evaluated the association of IDH mutation status with PROs and/or cognitive functioning of glioma patients were identified from the Pubmed/MEDLINE, Clarivate analytics, and Google Scholar databases. Eight studies (7 journal articles and 2 conference abstracts) with a total of 658 low-grade glioma and high-grade glioma patients investigated the association of cognitive functioning and/or QoL with IDH status. IDH-WT status was associated with greater cognitive impairment relative to IDH-Mut status in three studies, while one study did not find the association between IDH status and perioperative cognitive functioning. One study reported worse postoperative cognitive functioning patients with IDH-WT vs. IDH-mut gliomas. In one study, IDH-WT status was linked to greater impairment on physical and communication functioning after surgery. IDH-WT gliomas are associated with greater cognitive burden than IDH-Mut tumors. The association of IDH status with QoL remains less clear. Assessment of IDH status should be considered when evaluating QoL and cognitive complaints of glioma patients. Further studies linking glioma molecular phenotypes with PROs and cognitive functioning are encouraged.
异柠檬酸脱氢酶（IDH）突变状态对胶质瘤患者具有重要的预后意义，与 IDH 野生型（IDH-WT）相比，IDH 突变型（IDH-mut）胶质瘤患者的预后更差，生存时间更短。优化生活质量是胶质瘤患者管理的首要任务。本系统综述的目的是确定探讨 IDH 突变状态与胶质瘤患者报告结局（PRO）和认知功能之间关系的研究。
从 Pubmed/MEDLINE、Clarivate analytics 和 Google Scholar 数据库中确定了评估 IDH 突变状态与胶质瘤患者 PRO 和/或认知功能之间关系的研究。八项研究（7 篇期刊文章和 2 篇会议摘要）共纳入 658 例低级别胶质瘤和高级别胶质瘤患者，探讨了认知功能和/或生活质量与 IDH 状态的关系。三项研究表明，IDH-WT 状态与 IDH-Mut 状态相比，认知障碍更为严重，而一项研究未发现 IDH 状态与围手术期认知功能之间的关联。一项研究报告称，与 IDH-mut 胶质瘤相比，IDH-WT 胶质瘤患者术后认知功能更差。在一项研究中，IDH-WT 状态与术后身体和沟通功能障碍的程度更大有关。IDH-WT 胶质瘤比 IDH-Mut 肿瘤具有更大的认知负担。IDH 状态与生活质量的关联尚不清楚。在评估胶质瘤患者的生活质量和认知主诉时，应考虑评估 IDH 状态。鼓励开展更多将胶质瘤分子表型与 PRO 和认知功能联系起来的研究。
